Paliperidone Long-Acting Injection: 3 Brands Compared

About paliperidone long-acting injection

Paliperidone long-acting injection is an

antipsychotic medicine

primarily used for the maintenance treatment of

schizophrenia in adults

. It is available under brand names such as

Xeplion®

(monthly),

Trevicta®

(three-monthly), and

Byannli®

(six-monthly), administered as a long-acting intramuscular depot injection.

These formulations are designed for patients whose symptoms have been stabilized with oral antipsychotics like paliperidone or risperidone. The depot injection slowly releases the active substance, paliperidone palmitate, into the bloodstream over extended periods, reducing the need for daily tablets. This approach improves adherence, particularly for those who struggle with remembering daily medication, erratic clinic attenders, or individuals experiencing injection site reactions with more frequent doses.

Paliperidone Long-Acting Injection Overview

Type of Medicine	Used For	Brands	Available As
An antipsychotic medicine	Schizophrenia in adults	Xeplion®; Trevicta®; Byannli®	Long-acting intramuscular depot injection

The

main advantage

of these injections is convenience: Xeplion requires monthly administration, Trevicta every three months, and Byannli every six months. Paliperidone can remain detectable in plasma for up to 18 months after Trevicta and potentially 4 years after Byannli, emphasizing the need for careful tolerability assessment before switching.

Key facts about paliperidone long-acting injection

• Paliperidone is a second-generation (atypical) antipsychotic that works by blocking dopamine and serotonin receptors in the brain, helping to control schizophrenia symptoms like hallucinations, delusions, and disorganized thinking.
• Treatment begins after stabilization on oral therapy; long-acting forms are for maintenance only, not acute episodes.
• Injections are given by healthcare professionals into the deltoid (upper arm) or gluteal (buttocks) muscle.
• Dose adjustments are based on response and tolerability; not suitable for rapid switches from oral meds due to slow release profile.
• Women of childbearing potential should use contraception, as paliperidone persists long-term in the body.

How paliperidone long-acting injection is given

Before starting, read the manufacturer’s

printed information leaflet

for full details on paliperidone, including side effects. Injections are administered by a doctor or nurse.

Initiation for Xeplion (1-monthly)

For patients new to paliperidone injection:

• First dose:

  150 mg

  into deltoid muscle.
• Second dose (1 week later):

  100 mg

  into deltoid.
• Subsequent monthly doses: 75-150 mg, adjusted as needed, into deltoid or gluteal.

Switching to Trevicta (3-monthly)

Available for clinically stable patients on Xeplion. Criteria include at least 4-6 consecutive monthly doses at the same dose. Administer Trevicta at the time the next Xeplion dose is due (±7-14 days). Doses correspond to prior monthly dose (e.g., 175 mg Trevicta after 75 mg Xeplion).

Switching to Byannli (6-monthly)

For patients stable on Trevicta (preferably 4+ months). Administered every 6 months (±14 days) into gluteal muscle only. Dosing based on prior Trevicta dose.

Administration tips: Shake syringe vigorously for 15 seconds before injection to ensure suspension homogeneity. Use appropriate needles (e.g., 22G 1½” for gluteal). Inject slowly into deep muscle.

Missed doses

Missed Dose Guidance for Trevicta

Time Since Last Injection	Action
>3.5 up to 4 months	Administer ASAP, resume 3-monthly schedule
4-9 months	Re-initiate with 1-monthly regimen (two deltoid doses 1 week apart), then resume Trevicta
>9 months	Restart with 1-monthly Xeplion (4+ months), then Trevicta

Similar protocols apply for Byannli, consulting SmPC for details.

Getting the most from your treatment

• Attend all injection appointments; if missed, reschedule immediately.
• Continue any prescribed oral antipsychotics as directed during transition.
• Monitor for side effects; report persistent issues to your doctor.
• Avoid alcohol, as it may worsen side effects.
• Regular blood tests or monitoring may be needed for long-term use.

If you experience any problems

Common side effects

• Headache, insomnia, weight gain, akathisia (restlessness), injection site reactions.

Serious side effects (seek urgent help)

• Neuroleptic malignant syndrome (fever, stiff muscles, confusion).
• Tardive dyskinesia (involuntary movements).
• High blood sugar, heart rhythm changes, severe allergic reactions.

Contact your doctor if you have risk factors like liver/kidney issues, cardiovascular disease, epilepsy, Parkinson’s, glaucoma, or myasthenia gravis.

Who should not take paliperidone?

• Allergy to paliperidone or risperidone.
• Current breast-feeding.
• Known heart conditions or QT prolongation risk.
• Recent jaundice or blood disorders.

Frequently Asked Questions (FAQs)

Q: How often are paliperidone injections given?

A: Xeplion monthly, Trevicta every 3 months, Byannli every 6 months, after initial stabilization.

Q: Can I switch from oral antipsychotics directly to Trevicta?

A: No, stabilize on 1-monthly Xeplion first (at least 4-6 doses), then switch if stable.

Q: What if I miss an injection appointment?

A: Reschedule ASAP; follow missed dose guidelines based on time elapsed.

Q: Is paliperidone safe for long-term use?

A: Yes for maintenance in stable patients, but requires monitoring for side effects like movement disorders or metabolic changes.

Q: Where is the injection given?

A: Deltoid (arm) for initiation/monthly; deltoid or gluteal for longer-acting forms.

Further information

Always consult the Summary of Product Characteristics (SmPC) or your healthcare provider for personalized advice. Paliperidone LAIs represent a significant advancement in schizophrenia management, improving patient outcomes through better adherence.